TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Super Power in BAI

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* meet candidacy criteria for a high gain super-power processor with a fitting range up to 65 dB~* native English speaker~Exclusion Criteria:~* do not meet inclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort (Type: None): Hearing and speech tests will be performed on the subject and repeated to compare results obtained using their current BAHA processor against results using super-power BAHA processor.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone and Block Duration in Upper Extremity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* age 18-75, no contraindication to regional anesthesia,~Exclusion Criteria:~* opioid user, chronic pain conditions, peripheral neuropathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Bupivacaine (Type: ACTIVE_COMPARATOR): Control
- Bupivacaine with Dexamethasone (Type: EXPERIMENTAL): Dexamethasone will be mixed with bupivacaine
- Intravenous Dexamethasone (Type: ACTIVE_COMPARATOR): Dexamethasone will be given intravenously

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Axial Alignment in Patients Operated Using the Visionaire Patient Matched Cutting Blocks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Indication for TKA, Axial alignment between 10 degrees valgus and 20 degrees varus, BMI \<36, patient must be amendable for both Genesis II total knee and Visioniare cutting blocks~Exclusion Criteria:~* Insufficient femoral or tibia bone stock, inflammatory arthritis (e.g. rheumatoid arthritis), patient is immunosuppressed, has an active infection (local or systemic), patient has physical, emotional or neurological conditions that would compromise the patients compliance with rehabilitation and follow up.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Visionaire (Type: EXPERIMENTAL): the group who will be operated by the use of Visionaire patient matched cutting blocks
- Standard Surgical technique (Type: ACTIVE_COMPARATOR): The group who will be operated by means fo standard surgical technique

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Non-interventional Comparison of Sedatives on Weaning From Mechanical Ventilation in Intensive Care Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Admitted to a general ICU ward~* ≥ 18years~* Intubated and mechanically ventilated for at least 24 hours~* Need of light to moderate sedation (corresponding to RASS 0 - (-3) or MAAS 2-3)~* Sedated with dexmedetomidine, midazolam and/or propofol~* Good knowledge in Swedish language~* Signed informed consent~Exclusion criteria:~* Lack of fulfilling prescribed sedation regime~* Estimated high risk of death during the study period, according to investigator (roughly equal to estimated mortality rate (EMR) \> 80% )~* Tracheotomy~* Change in sedative drugs since the fit for weaning time point~* Use of other alpha-2 agonists (clonidine) during ICU stay~* Positive pregnancy test or currently lactating/ known pregnancy or lactation~* Participation in other study involving use of a pharmacologically active compound~* Patients with limitations in therapy~* Otherwise unable to fulfill the study, according to investigator's opinion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine (Type: None): Here, patients to be included are those being sedated with dexmedetomidine as primary sedative.
- Propofol (Type: None): Here, patients to be included are those being sedated with propofol as primary sedative.
- Midazolam (Type: None): Here, patients to be included are those being sedated with midazolam as primary sedative

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* COVID-19 infected patient~* Age 18 years or older~* Presence of pneumonia~* PaO2/FiO2 \< 300 mm Hg or SpO2 \< 93% in air ambient or need to supplementary oxygen administration in order to maintain SpO2 range in \[94-98%\] or lung infiltrates \> 50%~* Medical insurance~Exclusion Criteria:~* Presence of do-not-resuscitate order~* Pregnancy~* Prisoners~* Known Naproxen allergy or intolerance~* Severe renal failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1: Naproxen (Type: EXPERIMENTAL): Administration of naproxen 250 mg twice and lansoprazole 30 mg daily for prevention of gastropathy induced by stress or a nonsteroidal anti-inflammatory drug (NSAID) in addition to standard of care (SOC)
- 2: Standard of care (Type: PLACEBO_COMPARATOR): Standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Magnetic Resonance-guided High Intensity Focused Ultrasound for the Ablation of Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Informed Consent as documented by signature~* World Health Organization (WHO) performance status≤ 2~* Body weight ≤ 80 kg~* Biopsy proven invasive breast cancer with a size of ≤3.0cm (TNM classification: cT1-2 N0-2 MX ).~* Histological type of tumor: invasive ductal carcinoma (IDC)~* Patient is scheduled for surgical resection of tumor at study site~* Tumor location within the reach of the HIFU transducers with the patient in prone position; distance from skin and pectoral muscle to the tumor ≥ 1.0 cm.~* Target breast fits in the cup of the dedicated MR-HIFU breast system~Exclusion Criteria:~* neoadjuvant systemic therapy~* prior radiotherapy in target breast~* contraindications for MRI~* contraindication for application of gadolinium-based contrast agent~* contraindication for procedural sedation analgesia~* macro-calcifications in or around the targeted tumor~* scar tissue or surgical clips in the direct path of the ultrasound beams~* Women who are pregnant or breast feeding,~* Intention to become pregnant during the course of the study,~* Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases.~* Known or suspected non-compliance, drug or alcohol abuse,~* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,~* Participation in another study with investigational drug/device within the 30 days preceding and during the present study,~* Previous enrolment into the current study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MR-HIFU treatment (Type: EXPERIMENTAL): Patients with breast cancer and scheduled surgical resection (lumpectomy or mastectomy) will be treated with Philips Sonalleve® MR-HIFU Breast Therapy System prior to surgery in a treat\& resect model

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Neuroserpin as an Autism Candidate Gene

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Autistic patient, or first degree relative of autistic patient~Exclusion Criteria:~* Less than one year of age.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: None): Autistic patients.
- 2 (Type: None): Matched controls

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Investigate The Safety And Toleration Of Multiple Oral Doses Of PF-03654764 In Combination With Fexofenadine In Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects. (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).~Exclusion Criteria:~* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).~* A positive urine drug screen.~* Treatment with an investigational drug within 30 days (or as determined by the local requirement, whichever is longer) or 5 half-lives preceding the first dose of study medication.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- PF-03654764 2.5mg plus fexofenadine 60mg (Type: EXPERIMENTAL): None
- PF-03654764 5mg plus fexofenadine 60mg (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Rhubarb and Angiotensin Converting Enzyme Inhibitor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients \>18 years~2. Patients with diabetic nephropathy (history of type 1 or type 2 diabetes for \> 7 years, no other cause for proteinuria listed in their medical chart). This is the definition used in most peer-reviewed trials44,45 of diabetic nephropathy. We do recognize that their proteinuria could be due to some other concomitant kidney disease but the only way to confirm that is to do a kidney biopsy which is not clinically justified.~3. Proteinuria ≥ 0.5 g/day~4. Ability to sign consent form~Exclusion Criteria:~1. Pre study GFR (see section 10.7) \< 20 ml/min~2. Renal disease of etiologies other than diabetes~3. Uncontrolled hypertension (Systolic BP \>180 mmHg and Diastolic BP \>110mm Hg)~4. Patients with history of kidney stones in past 10 years~5. Patients with active chronic liver disease (Liver enzymes ALT, AST \>2.5 times normal)~6. Patients with primary small bowel disease with malabsorption, blind loop syndrome, or jejunoileal bypass surgery (may cause unabsorbed fatty acids to combine with calcium which in turn causes too much absorption of oxalate)~7. Patients with current alcohol, illicit drug use or any other condition (eg. Psychiatry disorder) that in the opinion of the investigator may interfere with the patient's ability to comply with the study~8. Pregnant women or women of child bearing potential who are unwilling to use an adequate form of contraceptive during the course of the study (ACEI may be fetotoxic)~9. Patients with significant unstable cardiovascular disease (NYHA class III and IV)~10. Patients with active malignancy~11. Uncontrolled infections.~12. Patients with a known sensitivity to the study medications (including enalapril)~13. Patients on angiotensin II receptor blockers (ARBs)~14. Microscopic or macroscopic hematuria (to rule out kidney disease other than diabetic nephropathy)~15. Patients on any herbal supplements unwilling to discontinue them~16. Severe malnutrition (serum albumin \<2.6mg/dL)~17. Hyperkalemia at baseline, defined as serum potassium ≥ 5.5 mg/dL~18. Iodine allergy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rhubarb extract (Type: EXPERIMENTAL): will receive rhubarb extract
- placebo (Type: PLACEBO_COMPARATOR): receive placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate SBI in the Dietary Management of Mild to Moderate Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of mild to moderate Crohn's disease for at least 3 months.~* Screening CDAI between \>150 and ≤ 250 based on subject recall.~* Average of greater than two liquid or soft stools per day and an abdominal pain intensity score \>1.~* Subject has at least one positive biomarker of inflammation: fecal calprotectin \>100 µg/g; elevated C-reactive protein (CRP) \>2 mg/dL.~Exclusion Criteria:~* Positive stool test for pathogenic bacteria including Clostridium difficile or O\&P.~* Confirmed intestinal stricture with obstructive-like clinical symptoms.~* Bowel resection within the previous 6 months.~* Change in medical therapy: must have been on a stable dose of~  * corticosteroids (prednisone or prednisolone) less than or equal to 20 mg per day for 2 weeks prior to screening,~ * budesonide less than or equal to 9 mg per day for 2 weeks prior to screening,~ * 5-aminosalicylates for 2 weeks prior to screening, and~ * immunomodulators for 6 weeks prior to screening.~* Taking greater than 20 mg per day of a corticosteroid (prednisone or prednisolone) or greater than 9 mg of budesonide.~* Received biologic therapy in past 2 years.~* Diagnosis of one or more co-morbid condition (s) requiring medical or surgical therapy that may affect bowel function, gastrointestinal symptoms.~* Serious infection in the 3 months prior to enrollment.~* Allergy or intolerance to beef or to any ingredient used in the product.~* Participated in an investigational drug or device study within 30 days.~* Does not have access to the internet.~* Taken EnteraGam®

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SBI 10 g BID (Type: ACTIVE_COMPARATOR): Serum-derived Bovine Immunoglobulin / Protein Isolate (SBI) 10.0 grams twice per day
- Placebo BID (Type: PLACEBO_COMPARATOR): Placebo w/control protein

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Broad Clinical Benefit for Seroquel XR With Flexible Dose as an add-on Therapy in the Treatment of Acute Bipolar Mania Patients With Partial Response to Current Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented clinical diagnosis meeting the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria (1. Bipolar I Disorder, manic or mixed type with/without psychotic feature, 2. Diagnosis should be confirmed by the Mini Inte)~* Currently on Lithium/Valproate without antipsychotics more than 3 weeks consecutive treatment YMRS total score ≥16 at study entry~Exclusion Criteria:~* Non-response to antipsychotic treatments for manic symptoms in previous episodes~* A patient with Diabetes Mellitus (DM) fulfilling one of the following criteria (1. Unstable DM defined as enrolment glycosylated hemoglobin (HbA1c) \>8.5%, 2. Admitted to hospital for treatment of DM or DM related illness in past 12 weeks, etc)~* An absolute neutrophil count (ANC) of 1.5 x 10\^9 per liter

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Quetiapine XR (Type: EXPERIMENTAL): Quetiapine fumarate (Seroquel XR)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Peri-procedural Smoking Cessation Program in Patients With Chronic Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Chronic Pain of 3 months or greater~* Scheduled for interventional pain procedure~Exclusion Criteria:~* Cancer related pain~* Current participation in smoking abstinence program~* History of schizophrenia or other pyschotic disorder~* History of dementing illness~* Pregnant patients~* Diagnosis of depression or anxiety

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Cryoablation for Abdominal Pain Associated With Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must be at least 18 years old~* Subject has unresectable or inoperable pancreatic carcinoma as determined by CT or MRI~* Subject's epigastric/abdominal 'worst pain' in the last 24 hours must be reported to be 4 or above on a scale of 0 (no pain) to 10 (pain as bad as subject can imagine) on the BPI despite pharmaceutical pain management~* ECOG of 0-3~* Platelet count \>50,000~* INR \<1.5~Exclusion Criteria:~* Subject's life expectancy is \<3 months~* Subject has current neutropenia (ANC \<1000)~* Subject unable to undergo CT or MRI~* Subject had previous ETOH neurolytic block for pancreatic cancer-related pain less than 2 weeks from screening~* Subject had surgery \<4 weeks from screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cryoablation (Type: OTHER): Freezing of the celiac plexus

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Modified Mirror Therapy in Patients With Upper Limb Hemiparesis After Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meeting the diagnostic criteria of stroke, by CT or MRI.~* The first-onset stroke.~* Presenting with unilateral upper limb dysfunction, within Brunnstrom stage Ⅱ to Ⅳ on the affected side, and Ash-worth score ≤2.~* No obvious cognitive impairment, with Mini-Mental State Examination (MMSE) score \>21 points.~* National Institutes of Health Stroke Scale (NIHSS) score \>4 points.~* Stable vital signs, no severe diseases such as cancer, liver or kidney disorders.~* Aged 35-70 years.~* Courses of diseases 2-6 weeks.~Exclusion Criteria:~* Presence of aphasia, apraxia, or hemispatial neglect.~* Presence of hearing, vision, or comprehension impairments that hinder diagnosis and treatment.~* Complicate with traumas, fractures, or other progressive neuro-muscular system diseases.~* Severe spasticity in the upper limbs.~* Severe bone, joint, or muscle deformities or lesions.~* History of mental illness.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- modified mirror therapy+Modified mirror therapy (Type: EXPERIMENTAL): The study lasted 30 days for each participant. The patients enrolled were randomly divided into the experimental group and the control group, all under routine rehabilitation therapy. Additionally, the patients in the experimental group were given modified mirror therapy.
- routine rehabilitation therapy (Type: ACTIVE_COMPARATOR): The study lasted 30 days for each participant. The patients enrolled were randomly divided into the experimental group and the control group, all under routine rehabilitation therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval